Browse ACPP

Summary
SymbolACPP
Nameacid phosphatase, prostate
Aliases ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location3q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Secreted ; SUBCELLULAR LOCATION: Isoform 2: Cell membrane Single-pass type I membrane protein Lysosome membrane Single-pass type I membrane protein Note=Appears to shuttle between the cell membrane and intracellular vesicles. Colocalizes with FLOT1 at cell membrane and in intracellular vesicles (PubMed:17638863). Colocalizes with LAMP2 on the lysosome membrane (PubMed:17897319).
Domain PF00328 Histidine phosphatase superfamily (branch 2)
Function

A non-specific tyrosine phosphatase that dephosphorylates a diverse number of substrates under acidic conditions (pH 4-6) including alkyl, aryl, and acyl orthophosphate monoesters and phosphorylated proteins. Has lipid phosphatase activity and inactivates lysophosphatidic acid in seminal plasma.; FUNCTION: Isoform 2: the cellular form also has ecto-5'-nucleotidase activity in dorsal root ganglion (DRG) neurons. Generates adenosine from AMP which acts as a pain suppressor. Acts as a tumor suppressor of prostate cancer through dephosphorylation of ERBB2 and deactivation of MAPK-mediated signaling.

> Gene Ontology
 
Biological Process GO:0001973 adenosine receptor signaling pathway
GO:0006144 purine nucleobase metabolic process
GO:0006766 vitamin metabolic process
GO:0006767 water-soluble vitamin metabolic process
GO:0006772 thiamine metabolic process
GO:0006790 sulfur compound metabolic process
GO:0008277 regulation of G-protein coupled receptor protein signaling pathway
GO:0009112 nucleobase metabolic process
GO:0009116 nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0016311 dephosphorylation
GO:0019233 sensory perception of pain
GO:0031644 regulation of neurological system process
GO:0035587 purinergic receptor signaling pathway
GO:0035588 G-protein coupled purinergic receptor signaling pathway
GO:0042278 purine nucleoside metabolic process
GO:0042723 thiamine-containing compound metabolic process
GO:0044057 regulation of system process
GO:0045745 positive regulation of G-protein coupled receptor protein signaling pathway
GO:0046085 adenosine metabolic process
GO:0046128 purine ribonucleoside metabolic process
GO:0051930 regulation of sensory perception of pain
GO:0051931 regulation of sensory perception
GO:0060167 regulation of adenosine receptor signaling pathway
GO:0060168 positive regulation of adenosine receptor signaling pathway
GO:0072527 pyrimidine-containing compound metabolic process
GO:1901657 glycosyl compound metabolic process
Molecular Function GO:0003993 acid phosphatase activity
GO:0008252 nucleotidase activity
GO:0008253 5'-nucleotidase activity
GO:0016791 phosphatase activity
GO:0042131 thiamine phosphate phosphatase activity
GO:0042578 phosphoric ester hydrolase activity
GO:0052642 lysophosphatidic acid phosphatase activity
Cellular Component GO:0005765 lysosomal membrane
GO:0030175 filopodium
GO:0098852 lytic vacuole membrane
GO:0098858 actin-based cell projection
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
Summary
SymbolACPP
Nameacid phosphatase, prostate
Aliases ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location3q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ACPP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ACPP and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23152566Prostate carcinomaPromote immunityUsing samples from prostate cancer patients immunized with a DNA vaccine encoding prostatic acid phosphatase (PAP) and a trans-vivo delayed-type hypersensitivity (tvDTH) assay, we found that the detection of PAP-specific effector responses after immunization was prevented by the activity of PAP-specific regulatory cells.
24338683Prostate CarcinomaPromote immunityProstatic acid phosphatase (PAP) is a prostate-specific protein overexpressed in 95% of prostate tumours. The PAP-114-128 epitope elicits CD4(+) and CD8(+) T-cell-specific responses in C57BL/6 mice. Furthermore, when immunised in a DNA vector format (ImmunoBody®), PAP-114-128 prevents and reduces the growth of transgenic adenocarcinoma of mouse prostate-C1 prostate cancer cell-derived tumours in both prophylactic and therapeutic settings. This anti-tumour effect is associated with infiltration of CD8(+) tumour-infiltrating lymphocytes and the generation of high avidity T cells secreting elevated levels of IFN-γ.
Summary
SymbolACPP
Nameacid phosphatase, prostate
Aliases ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location3q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ACPP in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolACPP
Nameacid phosphatase, prostate
Aliases ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location3q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ACPP in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1210.872
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.3720.265
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.7950.444
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2420.605
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2790.826
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1940.898
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.9220.163
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8730.367
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.0640.293
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1270.847
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.4040.64
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1510.44
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ACPP in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolACPP
Nameacid phosphatase, prostate
Aliases ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location3q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ACPP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolACPP
Nameacid phosphatase, prostate
Aliases ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location3q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ACPP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ACPP.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolACPP
Nameacid phosphatase, prostate
Aliases ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location3q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ACPP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolACPP
Nameacid phosphatase, prostate
Aliases ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location3q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ACPP expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolACPP
Nameacid phosphatase, prostate
Aliases ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location3q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ACPP and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolACPP
Nameacid phosphatase, prostate
Aliases ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location3q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ACPP collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ACPP.
ID Name Drug Type Targets #Targets
DB03390N-Propyl-Tartramic AcidSmall MoleculeACPP1
DB03577Alpha-Benzyl-Aminobenzyl-Phosphonic AcidSmall MoleculeACPP1
DB06688Sipuleucel-TBiotechACPP1